Updates to our Terms of Use

We are updating our Terms of Use. Please carefully review the updated Terms before proceeding to our website.

Wednesday, April 23, 2025

View Back issues

Liver disease drug

NEW YORK — A Manhattan appeals court dismissed a securities fraud class action against French pharmaceutical firm Genfit over its drug to treat liver disease, finding the company disclosed clinical trial results and said its profitability could not be guaranteed.

Click here to read the ruling.

Categories / Appeals, Briefs, Health, Securities

Subscribe to our free newsletters

Our weekly newsletter Closing Arguments offers the latest about ongoing trials, major litigation and rulings in courthouses around the U.S. and the world, while the monthly Under the Lights dishes the legal dirt from Hollywood, sports, Big Tech and the arts.

Loading...